long intergenic non-protein coding RNA 2517Genealiases: []
Q-omics provides the consensus-scored LINC02517 profile across patient tissues and cancer cell-line models. LINC02517 expression is associated with patient survival in 6 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, LINC02517 is differentially expressed in 4, with the highest sampling consensus in BLCA. Additionally, LINC02517 RNA expression shows 5,602 significant gene co-expression associations, with the highest sampling consensus in SARC. Together, these results highlight KIRC, BLCA, and SARC as cancer lineages where LINC02517 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC02517 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC02517 survival associations across molecular data types. LINC02517 RNA expression shows survival associations in the most cancer types (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC02517 RNA expression–survival associations across cancer types. High LINC02517 expression shows unfavorable associations in KIRC, STAD, READ, TGCT and LGG, but favorable associations in SARC. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for LINC02517 RNA expression.
This table summarizes LINC02517 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in BLCA for RNA.
This table ranks reproducible tumor–normal expression differences for LINC02517. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC02517 shows lower tumor expression in BLCA, UCEC, BRCA and HNSC. The BLCA box plot shows higher LINC02517 RNA expression in normal versus tumor tissue (log2 FC = −0.186, t-test p = .004).
This table shows molecular features associated with LINC02517 in patient tissues and cancer cell lines. In patient samples, LINC02517 shows the broadest associations at the RNA and protein expression levels, with SARC recurring as the lineage with the largest associated feature set.
